336 related articles for article (PubMed ID: 32817629)
1. Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.
Di Yacovo S; Saumoy M; Sánchez-Quesada JL; Navarro A; Sviridov D; Javaloyas M; Vila R; Vernet A; Low H; Peñafiel J; García B; Ordoñez-Llanos J; Podzamczer D
PLoS One; 2020; 15(8):e0237739. PubMed ID: 32817629
[TBL] [Abstract][Full Text] [Related]
2. Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
[TBL] [Abstract][Full Text] [Related]
3. Association of Lower Adiponectin Plasma Levels, Increased Age and Smoking with Subclinical Atherosclerosis in Patients with HIV-1 Infection.
Bellinati PQ; Alfieri DF; Flauzino T; Junior PFG; Rossi DJ; Breganó JW; Simão ANC; de Almeida ERD; Lozovoy MAB; Reiche EMV
Curr HIV Res; 2020; 18(4):292-306. PubMed ID: 32516102
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.
Ross Eckard A; Longenecker CT; Jiang Y; Debanne SM; Labbato D; Storer N; McComsey GA
HIV Med; 2014 Oct; 15(9):537-46. PubMed ID: 24650269
[TBL] [Abstract][Full Text] [Related]
5. Association of subclinical atherosclerosis with lipid levels amongst antiretroviral-treated and untreated HIV-infected women in the Women's Interagency HIV study.
Parrinello CM; Landay AL; Hodis HN; Gange SJ; Norris PJ; Young M; Anastos K; Tien PC; Xue X; Lazar J; Benning L; Tracy RP; Kaplan RC
Atherosclerosis; 2012 Dec; 225(2):408-11. PubMed ID: 23089369
[TBL] [Abstract][Full Text] [Related]
6. Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.
Hileman CO; Kinley B; Scharen-Guivel V; Melbourne K; Szwarcberg J; Robinson J; Lederman MM; Mccomsey GA
J Infect Dis; 2015 Aug; 212(3):345-54. PubMed ID: 25583168
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients.
Mangili A; Ahmad R; Wolfert RL; Kuvin J; Polak JF; Karas RH; Wanke CA
Clin Infect Dis; 2014 Mar; 58(6):893-900. PubMed ID: 24336757
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters.
Bianconi V; Schiaroli E; Pirro M; Cardaci S; Busti C; Mannarino MR; Baldelli F; Francisci D
HIV Med; 2020 Sep; 21(8):512-522. PubMed ID: 32496664
[TBL] [Abstract][Full Text] [Related]
9. Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
Saumoy M; Ordóñez-Llanos J; Martínez E; Ferrer E; Domingo P; Ribera E; Negredo E; Curto J; Sánchez-Quesada JL; Di Yacovo S; González-Cordón A; Podzamczer D
J Antimicrob Chemother; 2015 Apr; 70(4):1130-8. PubMed ID: 25538166
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) and HIV: Allele-Specific Apolipoprotein(a) Levels Predict Carotid Intima-Media Thickness in HIV-Infected Young Women in the Women's Interagency HIV Study.
Enkhmaa B; Anuurad E; Zhang W; Li CS; Kaplan R; Lazar J; Merenstein D; Karim R; Aouizerat B; Cohen M; Butler K; Pahwa S; Ofotokun I; Adimora AA; Golub E; Berglund L
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):997-1004. PubMed ID: 28336560
[TBL] [Abstract][Full Text] [Related]
12. ASYMMETRIC DIMETHYLARGININE LEVELS AND ATHEROSCLEROSIS MARKERS IN CUSHING SYNDROME.
Ozsurekci CG; Akturk M; Ozkan C; Gulbahar O; Altinova AE; Yalcin M; Arslan E; Toruner F
Endocr Pract; 2016 Sep; 22(9):1088-95. PubMed ID: 27359292
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Biomarkers and Carotid Thickness in HIV Infected Patients under Antiretroviral Therapy, Undetectable HIV-1 Viral Load, and Low Cardiovascular Risk.
Leite KME; Santos Júnior GG; Godoi ETAM; Vasconcelos AF; Lorena VMB; Araújo PSR; Lima KO; Lacerda HR
Arq Bras Cardiol; 2020 Jan; 114(1):90-97. PubMed ID: 31664319
[TBL] [Abstract][Full Text] [Related]
14. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
[TBL] [Abstract][Full Text] [Related]
15. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy.
Baker JV; Neuhaus J; Duprez D; Cooper DA; Hoy J; Kuller L; Lampe FC; Liappis A; Friis-Moller N; Otvos J; Paton NI; Tracy R; Neaton JD;
AIDS; 2011 Nov; 25(17):2133-42. PubMed ID: 21857489
[TBL] [Abstract][Full Text] [Related]
16. Dyslipidemia, chronic inflammation, and subclinical atherosclerosis in children and adolescents infected with HIV: The PositHIVe Health Study.
Augustemak de Lima LR; Petroski EL; Moreno YMF; Silva DAS; Trindade EBMS; Carvalho AP; Back IC
PLoS One; 2018; 13(1):e0190785. PubMed ID: 29320547
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
[TBL] [Abstract][Full Text] [Related]
18. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
Saumoy M; Sánchez-Quesada JL; Martínez E; Llibre JM; Ribera E; Knobel H; Gatell JM; Clotet B; Curran A; Curto J; Masó M; Ordoñez-Llanos J; Podzamczer D
Atherosclerosis; 2012 Nov; 225(1):200-7. PubMed ID: 23017355
[TBL] [Abstract][Full Text] [Related]
19. [Atherosclerosis in rheumatoid arthritis: the role of high-resolution B mode ultrasound in the measurement of the arterial intima-media thickness].
Carotti M; Salaffi F; Mangiacotti M; Cerioni A; Giuseppetti GM; Grassi W
Reumatismo; 2007; 59(1):38-49. PubMed ID: 17435841
[TBL] [Abstract][Full Text] [Related]
20. Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).
Nixon DE; Bosch RJ; Chan ES; Funderburg NT; Hodder S; Lake JE; Lederman MM; Klingman KL; Aberg JA;
J Clin Lipidol; 2017; 11(1):61-69. PubMed ID: 28391912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
